PRAGUE, Czech Republic and BASEL, Switzerland and CAMBRIDGE, Mass, April 12, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced interim safety and efficacy results from the ongoing Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, in combination with pembrolizumab in patients with advanced/metastatic solid tumors. The data were presented by Dr. Stephane Champiat from Gustave Roussy Cancer Center in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022. The company also presented findings from preclinical studies of its immunocytokine candidate SOT201, and of its CAR-T cancer therapy BOXR1030 in two poster presentations at the meeting.
Follow this link:
Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting
Recommendation and review posted by Fredricko
